PhaseV将在即将到来的活动中展示 AI在临床开发中的变革性应用-动脉网

PhaseV to Present Transformative Use of AI for Clinical Development at Upcoming Events

CISION 等信源发布 2025-04-08 20:30



可切换为仅中文







Presentations to Highlight the Power of Advanced Machine Learning for Enhancing Trial Design, Execution and Analysis

演示将突出先进机器学习在提升试验设计、执行和分析方面的强大能力

BOSTON

波士顿

，

April 8, 2025

2025年4月8日

/PRNewswire/ --

PhaseV

阶段V

, a leader in AI/ML-driven clinical development, today announced its participation in several upcoming biotech and data science conferences. The company will showcase its advancements in optimizing clinical trials using AI-powered analytics, biostatistics, and rigorous trial design to increase efficiency, ensure regulatory adherence, and accelerate treatments for a wide range of diseases, including oncology, inflammatory bowel disease and more..

，一家在AI/ML驱动的临床开发领域处于领先地位的公司，今天宣布将参与多个即将举行的生物技术和数据科学会议。该公司将展示其在利用人工智能分析、生物统计学和严格的试验设计优化临床试验方面的进展，以提高效率、确保合规性并加速针对多种疾病（包括肿瘤学、炎症性肠病等）的治疗进程。

'As clinical development becomes increasingly complex, integrating AI and advanced statistical modeling is essential to optimize efficiency and deliver results,' said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. 'We're excited to showcase how our rigorous scientific approach, unparalleled data assets, and novel use of real-world evidence are reshaping trial design, analysis and execution.'.

“随着临床开发变得日益复杂，整合人工智能和先进统计建模对于优化效率和交付成果至关重要，”PhaseV首席执行官兼联合创始人拉维夫·普里卢克博士表示。“我们很兴奋地展示我们的严谨科学方法、无与伦比的数据资产以及真实世界证据的创新应用如何重塑试验设计、分析和执行。”

Event participation includes:

活动参与包括：

IBD Innovate 2025

IBD创新2025

April 9-10

4月9日至10日

，

New York, NY

纽约，纽约州

PhaseV will showcase its advancements in the exhibition hall

PhaseV 将在展览大厅展示其进步成果。

Duke Industry Statistics Symposium 2025

杜克工业统计研讨会 2025

April 9-11

4月9日至11日

，

Durham, NC

北卡罗来纳州达勒姆市

•

Panel Session:

面板会议：

S1D – Recent Advances in Computing, Optimization, and Causal Inference for Adaptive Clinical Trials

S1D – 自适应临床试验中计算、优化与因果推断的最新进展

• Moderator:

• 主持人：

Brad Carlin

布拉德·卡林

, PhD, Senior Director, Data Science and Statistics at PhaseV

博士，PhaseV数据科学与统计高级总监

Presentations:

演示：

○

Causal Machine Learning for Estimating Uncertainty and Detecting Subgroups in Adaptive Clinical Trials

用于估计不确定性及在适应性临床试验中检测亚组的因果机器学习

Speaker

扬声器

: Raviv Pryluk, PhD, CEO and Co-founder, PhaseV

Raviv Pryluk，博士，PhaseV首席执行官兼联合创始人

○

To Bayes or Not to Bayes: Practical Challenges and Considerations in Supporting the Design of Adaptive Clinical Trials

贝叶斯还是非贝叶斯：支持适应性临床试验设计的实际挑战与考量

Speaker:

发言人：

Yaniv Fogel

亚尼夫·福格尔

, Algo Team Lead at PhaseV

PhaseV 的算法团队负责人

Joint Statistical Meetings (JSM) 2025

2025年联合统计会议 (JSM)

August 2-7

8月2日至7日

，

Nashville, TN

田纳西州纳什维尔

•

Presentations:

演示：

○

Recent Advances in Computing, Optimization, and Causal Inference for Adaptive Clinical Trials

自适应临床试验中计算、优化与因果推断的最新进展

Speakers:

扬声器：

Raviv Pryluk, PhD, CEO and Co-founder, PhaseV and

Raviv Pryluk，博士，PhaseV首席执行官兼联合创始人，

Brad Carlin

布拉德·卡林

, PhD, Senior Director, Data Science and Statistics at PhaseV

博士，PhaseV数据科学与统计高级总监

○

Innovative Statistical Methods for Robust Analysis from Small Samples

针对小样本稳健分析的创新统计方法

Speakers:

扬声器：

Elad Berkman

埃拉德·伯克曼

, PhD, CTO and Co-founder of PhaseV, Tzviel Frostig, PhD, Senior Data Scientist at PhaseV, Yaron Racah, Algorithms Developer at PhaseV, and

博士学位，PhaseV的首席技术官兼联合创始人茨维尔·弗罗斯蒂格博士，PhaseV的高级数据科学家雅龙·拉卡赫，PhaseV的算法开发人员。

Sofia Villar

索菲亚·维拉尔

, PhD, Programme Leader at MRC Biostatistics Unit,

，博士，MRC生物统计学部项目负责人，

University of Cambridge

剑桥大学

13th International Conference on Multiple Comparison Procedures (MCP 2025)

第13届多重比较程序国际会议（MCP 2025）

August 12-15

8月12日至15日

，

Philadelphia, PA

宾夕法尼亚州费城

Presentation:

展示：

Identifying Treatment Responders in Clinical Trials

识别临床试验中的治疗响应者

Speaker:

发言人：

Tzviel Frostig, PhD, Senior Data Scientist at PhaseV

茨维尔·弗罗斯蒂格，博士，PhaseV高级数据科学家

In addition,

此外，

Dan Goldstaub

丹·戈尔茨塔布

, PhD, PhaseV's Scientific Co-founder, and

，博士，PhaseV的科学联合创始人，以及

Hamza Sheikh

哈姆扎·谢赫

, Head of Business Development, will attend the

，业务发展主管，将出席

American Society of Clinical Oncology (ASCO) Annual Meeting

美国临床肿瘤学会（ASCO）年会

在

Chicago, IL

伊利诺伊州芝加哥

, from

，来自

May 30th to June 2nd

5月30日至6月2日

。

Since its founding, PhaseV's technology platform has been adopted by more than 30 global pharmaceutical and biotech companies, including industry leaders, to optimize clinical development and advance therapies in complex disease areas.

自成立以来，PhaseV的技术平台已被30多家全球制药和生物技术公司采用，其中包括行业领导者，以优化临床开发并推动在复杂疾病领域的治疗进展。

About PhaseV

关于 PhaseV

PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions.

PhaseV 正在开发先进的 AI/ML 解决方案以优化临床开发。生物制药公司和合同研究组织 (CRO) 正在利用 PhaseV 的平台快速设计和执行适应性、贝叶斯和固定临床试验，分析数据以揭示异质性治疗效果，对患者进行分层，并为未来的研发和产品组合决策提供信息。

PhaseV's platform has reduced trial costs by up to 25%, decreased enrollment size and trial duration by up to 40%, and increased the probability of trial success by up to 30%. To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others..

PhaseV的平台将试验成本降低了25%，将入组规模和试验时长减少了40%，并将试验成功的概率提高了30%。迄今为止，该公司已经为30多家领先的制药/生物技术公司和合同研究组织（CRO）提供了成果，涵盖多个治疗领域，包括神经学、肿瘤学、免疫学、胃肠病学、罕见病等。

Learn more at

了解更多请访问

www.PhaseVTrials.com

and follow us on

关注我们

领英

。

Media Contact:

媒体联系人：

Ellie Hanson

艾莉·汉森